Toxic neuropathy after adenine arabinoside treatment in chronic HBsAg-positive liver disease.
A 62-year-old woman with hepatitis-B-surface-antigen-positive hepatic cirrhosis presented with weakness and paresthesias over the distal part of the limbs in the course of adenine arabinoside 5'-monophosphate (ARA-AMP) treatment, and recovered spontaneously after several weeks of drug withdrawal. Electrophysiological and histological studies demonstrated axonal neuropathy. Although the patient received a relatively low total dose (120 mg/kg), her age and advanced liver disease may have played a role in the ARA-AMP neurotoxicity.
Kanterewicz
E
E
Liver Unit, Hospital Clínic i Provincial, University of Barcelona Medical School, Spain.
Bruguera
M
M
Viola
C
C
Lamarca
J
J
Rodés
J
J
D001088:Arabinonucleotides / Q000009:adverse effects*; D002908:Chronic Disease; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D001084:Vidarabine Phosphate / Q000009:adverse effects* / Q000627:therapeutic use
D001088:Arabinonucleotides; D006514:Hepatitis B Surface Antigens; D001084:Vidarabine Phosphate